Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates - Test2 - elhamkhani - TriplyDB

Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates

Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates

http://www.wikidata.org/entity/Q26853319

about

Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter Illicit dopamine transients: reconciling actions of abused drugs Neurotransmitter and psychostimulant recognition by the dopamine transporter.Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.The second sodium site in the dopamine transporter controls cation permeation and is regulated by chloride.Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site.Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency 2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations.Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.Changes in dopamine transporter binding in nucleus accumbens following chronic self-administration cocaine: heroin combinations Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine.Intermittent cocaine self-administration produces sensitization of stimulant effects at the dopamine transporter.Biological messiness vs. biological genius: Mechanistic aspects and roles of protein promiscuity.Tamoxifen and its active metabolites inhibit dopamine transporter function independently of the estrogen receptors.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter Conformational state interactions provide clues to the pharmacochaperone potential of serotonin transporter partial substrates.The role of human dopamine transporter in NeuroAIDS.Allosteric modulators: an emerging concept in drug discovery.Melatonin inhibits manganese-induced motor dysfunction and neuronal loss in mice: involvement of oxidative stress and dopaminergic neurodegeneration.The dopamine reuptake inhibitor MRZ-9547 increases progressive ratio responding in rats.Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.The unique psychostimulant profile of (±)-modafinil: investigation of behavioral and neurochemical effects in mice.Overview of Monoamine Transporters.Gβγ subunit activation promotes dopamine efflux through the dopamine transporter.Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes.Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.

P2860

Q21129426-1059A557-4DBC-445C-94D4-4608AA60D235 Q26771824-D5DFF3E9-64CB-4B51-9014-84009D7A3396 Q26829749-3FC9BF09-BDBF-4198-A2BF-C6CDBCA51D35 Q26997102-978A9ABB-729F-4293-A3A0-6B70718303AA Q27316816-918A8D37-CC7D-4ECE-B579-8A61F8006788 Q28545209-B241B50C-B91F-4D29-BB11-B23286A09066 Q30581669-3C003A91-70A1-4EAA-BB47-5200E710051F Q34170768-A99A1980-3404-4FF5-98C6-CF6AD76C1BB7 Q34396818-DF301EAD-19B4-44F2-A617-7E9D6F165C18 Q34467830-578515BE-6D78-4EEB-B1E2-328E815DF98A Q34509115-A81E5C2E-C0BB-461C-B992-4CFA03624639 Q34673305-AC0EFE6E-6017-4DD4-A1FC-1872D50836FF Q35160057-0675CC40-800C-40D2-A9B2-CDF3D42256BA Q35766564-55C2435F-8DFF-493B-957A-ACE4580CE431 Q36104010-0FFBC2F3-F1FF-4811-9ACD-F0E209C019E6 Q36392993-2E2E0C9C-B857-48E5-96C2-F8085FC8A4F9 Q36733500-EAE08E5A-BF6B-4ADF-950F-FB961B032E8A Q37707736-CDBD3E26-7365-48C4-9181-26B2101B2489 Q38248878-C0EF9B26-94D0-45EC-96C1-49679F31D49B Q38721916-407EAD1C-6A2B-44E0-B59E-141A61211124 Q38926644-8D6B8EC2-E843-4EE3-97C6-A73FF929DF8A Q39459667-A3DD0D92-F9B6-4A4B-A18D-AE4A9BA6395A Q40390385-E2F708AD-CC25-47CC-8886-1A600604255A Q41861390-A2E81087-F081-4CE1-9A03-A6D7D9A8EFA9 Q41922188-C5ED2FD7-20CE-424B-B331-8926657EFDD7 Q42097244-296DCED6-C2FA-4C52-9302-9DF05B0BCE2A Q42705031-AAF6C868-8175-4C4B-9ED1-5A0BBE6E22FD Q44707584-C2AFF664-65E3-41A3-A501-64BE3C66D3C3 Q46202005-4D7F5C40-D888-437F-BD54-B2F77A32C609 Q47103759-3F618CC0-9640-492C-9834-EF9333D11A04 Q47271566-CE17DC9C-C041-41FA-9146-775AFEDD8FB4 Q47624474-40544076-C5AE-47AF-BC1C-82ED60A1EEFB Q48184197-C684CF04-7CAE-4DBA-81AA-18B734AEC1E9 Q51009516-90CFE9B8-DC87-41AE-8D9C-1DDAFAD0605E Q52807144-A4B28D5A-6A04-4F70-B740-FC3EF938FD74

P2860

Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates

http://www.wikidata.org/entity/Q26853319

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Nonclassical pharmacology of t ...... lators, and partial substrates

@ast

Nonclassical pharmacology of t ...... lators, and partial substrates

@en

Nonclassical pharmacology of t ...... lators, and partial substrates

@nl

type

label

Nonclassical pharmacology of t ...... lators, and partial substrates

@ast

Nonclassical pharmacology of t ...... lators, and partial substrates

@en

Nonclassical pharmacology of t ...... lators, and partial substrates

@nl

prefLabel

Nonclassical pharmacology of t ...... lators, and partial substrates

@ast

Nonclassical pharmacology of t ...... lators, and partial substrates

@en

Nonclassical pharmacology of t ...... lators, and partial substrates

@nl

P1433

Q26853319-38D09211-5BD6-4369-9710-CD37CE897086

P1476

Q26853319-FEBB62E1-C6FC-48E6-8B3E-2D2A5068E6AD

P2093

Q26853319-08B4083B-3E8A-499B-A1BA-70247A35FB70

Q26853319-7FB938EA-B2BB-41DD-9AC8-82E39CA09AD9

Q26853319-EDCAAB67-2A5B-403A-ACE2-AE320DCCB106

P2860

Q26853319-00305A46-9949-48C8-8E99-698411507493

Q26853319-022E18F1-64DC-40CE-965F-FE9EBDFE722B

Q26853319-1262D9E4-E1DC-4737-817D-286A8BBAEA37

Q26853319-190BE63D-49E5-4774-8D99-E8B8F3F81078

Q26853319-1E3AAFFD-EF56-4F07-80CD-F45251B7D1C0

Q26853319-21C2C98D-9365-4199-803E-25A984BCF29F

Q26853319-236383A9-F7D4-4919-BD4D-27C4468AC939

Q26853319-2949C61C-94B1-489E-B2DB-A6AFFB679D4A

Q26853319-310AFA42-B481-4637-8281-60CF6AED6697

Q26853319-331BDEFB-3F75-4487-88E1-EDDD90E5C1D9

P304

Q26853319-CC1677C9-1877-4E85-8C52-16D9ABE5AA30

P31

Q26853319-25CA7517-A475-46F7-9260-88DC5D1769F4

P356

Q26853319-746146F0-21C5-4D74-A5CD-AB5E49EBDDCF

P407

Q26853319-E4A925E5-EFE7-4F80-87A2-09D56815949A

P433

Q26853319-24F1CF17-1635-4235-A71F-FF93BA979F65

P478

Q26853319-061B0524-FBD2-4ED7-9EAE-D1B681920633

P577

Q26853319-CC76FBDA-A427-479A-BEDD-328F6C495C4B

P5875

Q26853319-D0FF1635-846D-4F56-A6BA-1C8B567E8E98

P698

Q26853319-07759E0B-9A17-4295-8380-2A09850DB0BD

P921

Q26853319-33CFD8ED-8A14-46C5-B2B2-711B0032FDAF

Q26853319-6F1D4070-89B4-47F1-9927-FD7064D10DAA

Q26853319-c3caa620-4456-4927-b759-1195ef1b47a3

P932

Q26853319-0AC6E41E-DDCC-4D90-9BFC-1EDD92537639

P356

JPET.111.191056

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Nonclassical pharmacology of t ...... lators, and partial substrates

@en

P2093

K. C. Schmitt

http://www.w3.org/2001/XMLSchema#string

M. E. A. Reith

http://www.w3.org/2001/XMLSchema#string

R. B. Rothman

http://www.w3.org/2001/XMLSchema#string

P2860

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake

R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse

Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter

The binding sites for cocaine and dopamine in the dopamine transporter overlap

Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release

Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures

A competitive inhibitor traps LeuT in an open-to-out conformation.

Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation

Crystal structure of the carnitine transporter and insights into the antiport mechanism

P304

2-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.111.191056

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236140292

http://www.w3.org/2001/XMLSchema#string

P698

23568856

http://www.w3.org/2001/XMLSchema#string

P921

allosteric inhibitor

P932

3684841

http://www.w3.org/2001/XMLSchema#string